Halozyme Therapeutics, Inc. (HALO)

NASDAQ: HALO · USD

$130

+1.59 (+1.2%)· Recorded snapshot

Market cap	14.8B
Revenue (ttm)	1.7B
Net income (ttm)	413.6M
EPS (ttm)	$3.38
Shares out	113.5M
P/E (trailing)	38.5x
P/E (forward)	13.0x
Volume	1,011,881
Beta	0.88

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 1.7B
Net income (ttm): 413.6M
EPS (ttm): $3.38
P/E (trailing): 38.5x
P/E (forward): 13.0x
Market cap: 14.8B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Halten

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/E13

P25 n/aP50 n/aP75 n/a

Trailing P/E38.5

P25 n/aP50 n/aP75 n/a

ROE173.7

P25 n/aP50 n/aP75 n/a

ROIC32.1

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All HALO indicators

Market & fundamental data

Available fields

272

Groups with data

Currency

USD

Showing 272 of 272 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001159036
Company name	Halozyme Therapeutics, Inc.
Country	United States
Country code	US
CUSIP number	40637H109
Earnings date	2026-11-05
Earnings time	amc
Employees	423
Employees change	73
Employees growth	20.86%
Enterprise value	$16.7B
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	1998
Industry	Biotechnology
Is primary listing	Yes
Is SPAC	No
ISIN number	US40637H1095
Last 10-K release date	2026-02-17
Last earnings date	2026-08-06
Last refreshed	2026-10-28
Last stock split date	2003-12-10
Last stock split type	Forward
Market cap	$14.8B
Market cap category	Large-Cap
Next earnings date	2026-11-05
Options	Yes
Price	$130.09
Price currency	USD
Sector	Healthcare
SIC code	2836
Stock price date	2026-10-28
Symbol	HALO
U.S. state	California
Website	https://halozyme.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Adjusted P/E ratio	24.27x
Average P/E ratio (10Y)	29.98x
Average P/E ratio (3Y)	18.07x
Average P/E ratio (5Y)	19.37x
Earnings yield	2.6%
EV/Earnings	40x
EV/EBIT	17.51x
EV/EBITDA	15.74x
EV/FCF	20.52x
EV/Sales	9.94x
FCF / EV yield	4.87%
FCF yield	5.52%
Forward EV/Sales	8.14x
Forward P/E	13.01x
Forward P/S	7.18x
Graham number	9.78691
Graham upside	-92.39%
Lynch fair value	$42.54
Lynch upside	-66.92%
P/(FCF - SBC) ratio	19.64x
P/(OCF - SBC) ratio	19.32x
P/B ratio	102.09x
P/E ratio	38.46x
P/FCF ratio	18.1x
P/OCF ratio	17.83x
P/S ratio	8.77x
Price/EBITDA ratio	13.89x
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	56.77%
EBITDA margin	63.15%
Effective tax rate	29.1%
FCF margin	48.46%
Gross margin	76.27%
Operating margin	56.77%
Pretax margin	35.06%
Profit margin	24.86%
Profit per employee	$977,768
Profitable quarters	2
Profitable years	6
Revenue per employee	$3.9M
ROA	25.49%
ROA (5Y)	16.99%
ROCE	42.3%
ROE	173.67%
ROE (5Y)	183.15%
ROIC	32.13%
ROIC (5Y)	44.43%
SBC / revenue	3.79%
Tax / revenue	10.2%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth	-22.53%
EPS growth (Q)	42.86%
EPS growth (QoQ)	55.74%
EPS growth 3Y	25.71%
EPS growth 5Y	16.6%
EPS growth quarters	2
EPS growth years	0
FCF growth	49.11%
FCF growth (Q)	141.19%
FCF growth (QoQ)	34.24%
FCF growth 3Y	40.16%
FCF growth 5Y	40.07%
Gross profit growth	37.75%
Gross profit growth (Q)	42.91%
Gross profit growth 3Y	34.46%
Gross profit growth 5Y	32.8%
Net income growth	-25.78%
Net income growth (Q)	39.21%
Net income growth (QoQ)	53.23%
Net income growth 3Y	20.96%
Net income growth 5Y	12.58%
Net income growth quarters	2
Net income growth years	0
OCF growth	49.44%
OCF growth (Q)	141.59%
OCF growth (QoQ)	33.77%
OCF growth 3Y	38.84%
OCF growth 5Y	40%
Operating income growth	38.35%
Operating income growth (Q)	42.09%
Operating income growth 3Y	42.27%
Operating income growth 5Y	29.26%
Revenue growth	41.15%
Revenue growth (Q)	47.67%
Revenue growth (QoQ)	27.68%
Revenue growth 10Y	27.3%
Revenue growth 3Y	29.08%
Revenue growth 5Y	32.17%
Revenue growth quarters	18
Revenue growth years	7

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-12.4M
Depreciation and amortization	$106.2M
EBIT	$944.5M
EBITDA	$1.1B
EPS	$3.38
FCF per share	$7.10
Financing cash flow	$-110.8M
Free cash flow	$806.2M
Free cash flow minus SBC	$743.2M
Gross profit	$1.3B
Income taxes	$169.7M
Investing cash flow	$-605.7M
Net borrowing	$624.6M
Net cash flow	$102.1M
Net income	$413.6M
Operating cash flow minus SBC	$755.5M
Operating income	$944.5M
Revenue	$1.7B
Stock-based compensation	$63.1M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	4.19
Book value per share	$1.26
Debt / EBITDA	2.05
Debt / equity	15.18
Debt / FCF	2.7
Goodwill	$581.7M
Interest coverage	46.52
Long-term assets	$1.6B
Long-term liabilities	$2.1B
Net cash (debt)	$-1.9B
Net cash / market cap	-13.34%
Net debt / EBITDA	1.85
Net debt / equity	13.57
Net debt / FCF	2.42
Piotroski F-Score	5
Property, plant and equipment	$84.3M
Shareholders' equity	$143.5M
Tangible book value	$-1.4B
Tangible book value per share	$-11.93
Total assets	$2.6B
Total cash	$231M
Total debt	$2.2B
Total liabilities	$2.4B
WACC	7.98%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.72
Current assets	$933M
Current liabilities	$344.4M
Current ratio	2.71
Inventory turnover	2.48
Net working capital	$566.6M
Quick ratio	1.99
Working capital	$588.6M
Working capital turnover	2.11

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	4.21%
Dividend yield	0%
Shareholder yield	4.21%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	1,355.06%
10Y return CAGR	30.71%
10Y total return	1,355.06%
150-day SMA	$86.76
15Y price change	1,343.7%
15Y return CAGR	19.48%
15Y total return	1,343.7%
1D price change	1.24%
1M price change	13.7%
1M total return	13.7%
1W price change	4.13%
1W total return	4.13%
1Y price change	96.66%
1Y return CAGR	96.75%
1Y total return	96.66%
20-day SMA	$117.73
200-day SMA	$82.78
20Y price change	4,412.2%
20Y return CAGR	20.98%
20Y total return	4,412.2%
3M price change	58.94%
3M total return	58.94%
3Y price change	287.96%
3Y return CAGR	57.12%
3Y total return	287.96%
50-day SMA	$112.73
50-day SMA vs 200-day SMA	50over200
52-week high	$130.22
52-week high date	2026-10-28
52-week low	$61.23
52-week low date	2025-12-11
5Y price change	246.07%
5Y return CAGR	28.19%
5Y total return	246.07%
6M price change	100.81%
6M total return	100.81%
All-time high	$130.22
All-time high date	2026-10-28
All-time low	$1.41
All-time low date	2004-08-17
Average true range (ATR)	$3.23
Average volume	2.1M
Beta (1Y)	0.38
Beta (2Y)	0.24
Beta (5Y)	0.88
Change from 52-week high	-0.1%
Change from 52-week low	112.48%
Change from all-time high	-0.1%
Change from all-time low	9,084.4%
Change from open	2.75%
Day's gap	-1.47%
Dollar volume	$131.6M
High price	$130.22
Low price	$126.50
Monthly RSI	80.7
Open price	$126.61
Position in 52-week range	96.51%
Premarket change	-1.71%
Premarket close	$128.50
Premarket price	$126.30
Premarket volume	1.7K
Previous close	$128.50
Price vs 150-day SMA	49.26%
Price vs 20-day SMA	10%
Price vs 200-day SMA	56.44%
Price vs 50-day SMA	14.88%
Relative volume	0.47
RSI	78.13
Sharpe ratio	1.89
Sharpe ratio (3Y)	1.18
Sharpe ratio (5Y)	0.71
Sortino ratio	3.72
Sortino ratio (3Y)	1.91
Sortino ratio (5Y)	1.2
Volume	1M
Weekly RSI	78.48
YTD price change	92.42%
YTD total return	92.42%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	112.2M
Float percentage	98.85%
Shares change (QoQ)	-1.35%
Shares change (YoY)	-4.21%
Shares held by insiders	1.06%
Shares held by institutions	111.98%
Shares outstanding	113.5M
Short % of float	13.63%
Short % of shares	13.48%
Short ratio	6.5 days

Deeper analysis on HALO

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this HALO report

Is a complete HALO research report available?

No complete published report is available for Halozyme Therapeutics, Inc. (HALO) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Halozyme Therapeutics, Inc. (HALO)

Price

Financial snapshot

Fair-value bridge

Latest news · HALO

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All HALO indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on HALO

Frequently asked questions